# US 2016/0257718 A1 · Antimicrobial peptide wy-21 and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257718 A1
- Document ID: US20160257718A1
- Status: Published application
- Kind: A1
- Application number: 15/164,028
- Filed: 2016-05-25
- Published: 2016-09-08
- Earliest claimed: 2015-02-06
- Assignees: Zhejiang University
- Applicants: Zhejiang University
- Inventors: Yizhen Wang; Hongbo Yi
- Web page: https://patentgrep.com/patent/US20160257718A1

## CPC

- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61P 31/04: Antibacterial agents
- A61P 37/02: Immunomodulators
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An antimicrobial peptide WY-21 has amino acid sequence of Val-Lys-Phe-Phe-Arg-Lys-Leu-Lys-Lys-Ser-Val-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg. The antimicrobial peptide WY-21 can be used as broad-spectrum antibacterial agents for the treatment of Gram-negative or Gram-positive bacterial infection. It can also be applied for reducing immune system regulated inflammation.

## Claims

### Claim 1

An antimicrobial peptide, comprising the amino acid sequence of Val-Lys-Phe-Phe-Arg-Lys-Leu-Lys-Lys-Ser-Val-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg.

### Claim 2 (depends on 1)

The antimicrobial peptide of claim 1, wherein the antimicrobial peptide is a synthetic cationic peptide with an α-helix structure, 21 amino acid residues, a molecular weight of 2624.2 dalton (Da), isoelectric point of 10.79, and a net charge of +8.

### Claim 3 (depends on 1)

An antibacterial agent, comprising the antimicrobial peptide of claim 1.

### Claim 4 (depends on 3)

A method of treating Gram-positive or Gram-negative bacteria infection of a patient, comprising administrating the antibacterial agent of claim 3 to the patient.

### Claim 5 (depends on 1)

A method of reducing immune system regulated inflammation of a patient, comprising administrating the antimicrobial peptide of claim 1 to the patient.
